SCHEMBL207916

SCHEMBL207916

N#Cc1ccc(Nc2nc(-c3cccnc3)cs2)cc1C(F)(F)F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 2/20 0.62
NTSR1 P30989 1/20 0.62
MEN1 O00255 12/20 0.59
KMT2A Q03164 12/20 0.59
RAB9A P51151 8/20 0.59
MAPT P10636 5/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
NPC1 O15118 8/20 0.59
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
MAPK1 P28482 2/20 0.58
PKM P14618 2/20 0.56
GAA P10253 2/20 0.56
LMNA P02545 1/20 0.56
ALDH1A1 P00352 1/20 0.56
KIT P10721 2/20 0.54
CYP1A1 P04798 1/20 0.54
CYP1A2 P05177 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206371 0.85 MEN1 (0.67) VCPMEN1KMT2ARAB9AMAPT
SCHEMBL206432 0.84 MEN1 (0.76) VCPMEN1KMT2ARAB9AMAPT
SCHEMBL207250 0.84 MEN1 (0.68) VCPMEN1KMT2ARAB9AMAPT
SCHEMBL5023634 0.83 ABL1 (0.64) MEN1KMT2AGAAKIT
SCHEMBL3132659 0.82 MEN1 (0.53) VCPMEN1KMT2ARAB9AMAPT
SCHEMBL208059 0.81 MEN1 (0.52) VCPMEN1KMT2ARAB9AMAPT
SCHEMBL3128105 0.79 MEN1 (0.58) VCPMEN1KMT2ARAB9AMAPT
SCHEMBL2755821 0.79 MEN1 (0.67) VCPMEN1KMT2ARAB9AMAPT
SCHEMBL205600 0.79 MEN1 (0.71) VCPMEN1KMT2ARAB9AMAPT
SCHEMBL207658 0.79 MEN1 (0.75) VCPMEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 VCP 1270/4885NTSR1 2099/4885MEN1 3862/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 VCP 1270/4885NTSR1 2099/4885MEN1 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.